Key result
Early levosimendan is recommended for acute cardiac dysfunction, particularly with beta-blockers or ischemic cardiomyopathy.
Levosimendan is recommended as an early treatment option for acute cardiac dysfunction, particularly in patients with ischemic cardiomyopathy or those on beta-blockers, provided volume and potassium levels are managed.
May guide early levosimendan consideration in select acute cases; leaves open confirmation by prospective RCTs.
Levosimendan can be a valuable resource in the treatment of acute cardiac dysfunction, especially in the presence of beta-blockers or ischemic cardiomyopathy. When attention is given to avoiding or correcting hypovolemia and hypokalemia, an early use of the drug in the treatment algorithm is preferred.
No takes yet. Share an insight, caveat, or question.
Heringlake et al. (2021) studied this question. Levosimendan is recommended early for acute cardiac dysfunction, particularly with beta-blockers or ischemic cardiomyopathy, provided hypovolemia and hypokalemia are corrected.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: